Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick?

Authors: Hakan Ozer, Ismail Baloglu, Ali Topkac, Yasin Ozturk, Fethi Yonet, Furkan Daglı, İbrahim Kilinc, Kultigin Turkmen

Source: Nefrología, Vol 44, Iss 2, Pp 217-223 (2024)

Subject Terms: Enfermedad de Fabry, Periostina sérica, Proteinuria, Diseases of the genitourinary system. Urology, RC870-923

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0211699523000024; https://doaj.org/toc/0211-6995

Access URL: https://doaj.org/article/ea5ef2d047d744e9b2419f3e49bdec2c

Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick?

Authors: Hakan Ozer, Ismail Baloglu, Ali Topkac, Yasin Ozturk, Fethi Yonet, Furkan Daglı, İbrahim Kilinc, Kultigin Turkmen

Source: Nefrología (English Edition), Vol 44, Iss 2, Pp 217-223 (2024)

Subject Terms: Enfermedad de Fabry, Periostina sérica, Proteinuria, Diseases of the genitourinary system. Urology, RC870-923

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2013251423000779; https://doaj.org/toc/2013-2514

Access URL: https://doaj.org/article/bd462d5192d949e0befadb308d7694d2

Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors

Authors: Pınar Kubilay Tolunay, Bediz Kurt İnci, Şura Usta, Ali Topkaç, Berkan Karabuğa, Ergin Aydemir, İrem Öner, Büşra Akay Hacan, Öztürk Ateş, Cengiz Karaçin, Ülkü Yalçıntaş Arslan

Source: Current Oncology, Vol 31, Iss 12, Pp 7426-7436 (2024)

Subject Terms: CDK4/6 inhibitors, breast cancer, dose reduction, survival outcomes, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.mdpi.com/1718-7729/31/12/548; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729

Access URL: https://doaj.org/article/a9d0a88a93f74986b58a422fae315640